Therefore, this study approached breast cancer treatment with a dual-targeted therapy targeting HER2-mediated signaling (TZ treatment) and Mcl-1 mRNA (Mcl-1 nioplex treatment). The gene discussed is MCL1; the disease is breast carcinoma.